Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Ibrutinib in relapsed chronic lymphocytic leukemia.

Literature DB >> 24066758

Ibrutinib in relapsed chronic lymphocytic leukemia.

John C Byrd, Susan O'Brien, Danelle F James.

Abstract

Entities: Chemical Disease

Mesh：

Substances：

Year: 2013 PMID： 24066758 DOI： 10.1056/NEJMc1309710

Source DB: PubMed Journal: N Engl J Med ISSN： 0028-4793 Impact factor: 91.245

Keyword Cloud
Cited

× No keyword cloud information.

57 in total

Review 1. Targeted Therapy in Chronic Lymphocytic Leukemia.

Authors: Thomas J Kipps; Michael Y Choi
Journal: Cancer J Date: 2019 Nov/Dec Impact factor: 3.360

2. Characterization of CLL exosomes reveals a distinct microRNA signature and enhanced secretion by activation of BCR signaling.

Authors: Yuh-Ying Yeh; Hatice Gulcin Ozer; Amy M Lehman; Kami Maddocks; Lianbo Yu; Amy J Johnson; John C Byrd
Journal: Blood Date: 2015-04-01 Impact factor: 22.113

3. Response Rate as a Regulatory End Point in Single-Arm Studies of Advanced Solid Tumors.

Authors: Geoffrey R Oxnard; Katharine H Wilcox; Mithat Gonen; Mikhael Polotsky; Bradford R Hirsch; Lawrence H Schwartz
Journal: JAMA Oncol Date: 2016-06-01 Impact factor: 31.777

Review 4. Pembrolizumab and its role in relapsed/refractory classical Hodgkin's lymphoma: evidence to date and clinical utility.

Authors: Polina Shindiapina; Lapo Alinari
Journal: Ther Adv Hematol Date: 2018-03-05

5. Ibrutinib inhibits BCR and NF-κB signaling and reduces tumor proliferation in tissue-resident cells of patients with CLL.

Authors: Sarah E M Herman; Rashida Z Mustafa; Jennifer A Gyamfi; Stefania Pittaluga; Stella Chang; Betty Chang; Mohammed Farooqui; Adrian Wiestner
Journal: Blood Date: 2014-03-21 Impact factor: 22.113

6. Prognostic and Biologic Relevance of Clinically Applicable Long Noncoding RNA Profiling in Older Patients with Cytogenetically Normal Acute Myeloid Leukemia.

Authors: Ramiro Garzon; Clara D Bloomfield; Dimitrios Papaioannou; Deedra Nicolet; Hatice G Ozer; Krzysztof Mrózek; Stefano Volinia; Paolo Fadda; Andrew J Carroll; Jessica Kohlschmidt; Jonathan E Kolitz; Eunice S Wang; Richard M Stone; John C Byrd
Journal: Mol Cancer Ther Date: 2019-06-04 Impact factor: 6.261

Ibrutinib in relapsed chronic lymphocytic leukemia.

Review 1. Targeted Therapy in Chronic Lymphocytic Leukemia.

2. Characterization of CLL exosomes reveals a distinct microRNA signature and enhanced secretion by activation of BCR signaling.

3. Response Rate as a Regulatory End Point in Single-Arm Studies of Advanced Solid Tumors.

Review 4. Pembrolizumab and its role in relapsed/refractory classical Hodgkin's lymphoma: evidence to date and clinical utility.

5. Ibrutinib inhibits BCR and NF-κB signaling and reduces tumor proliferation in tissue-resident cells of patients with CLL.

6. Prognostic and Biologic Relevance of Clinically Applicable Long Noncoding RNA Profiling in Older Patients with Cytogenetically Normal Acute Myeloid Leukemia.

Review 7. Novel agents in follicular lymphoma: choosing the best target.

Review 8. The tumor microenvironment shapes hallmarks of mature B-cell malignancies.

Review 9. Ibrutinib in Waldenström macroglobulinemia: latest evidence and clinical experience.

Review 10. Targeting the B-cell receptor signaling pathway in B lymphoid malignancies.